NCAM1 and glioma: Patients with grade 3 glioma having a frequency of CD3−/CD56+ NK cells below a cut-off value of 10% were considered as part of the low CD3−/CD56+ NK cell group (n = 14; comprising 8 oligodendroglioma and 6 astrocytoma patients), whereas patients with a frequency of these NK cells above 10% were considered as being in the high CD3−/CD56+ NK cell group (n = 14; 5 oligodendroglioma, 9 astrocytoma).